Riassunto
Secondo questa teoria le alterazioni lipoproteiche, caratterizzate dall’ossidazione intravascolare delle LDL, contribuiscono in maniera rilevante a innescare e mantenere il processo infiammatorio aterogenetico. A questo proposito, diversi studi dimostrano che la riduzione dei livelli di colesterolo LDL plasmatico è fondamentale per diminuire il “carico aterogeno” negli anni e si associa a un significativo decremento degli eventi cardiovascolari [1]. La mortalità cardiovascolare è stata ridotta in seguito alla somministrazione di colestiramina, come evidenziato dallo studio LRC [2], e in seguito all’utilizzo di statine, come risulta dalle indagini WOSCOP [3], AFCAPS/TexCAPS [4], ASCOT-LLA [5], HPS [6] e più recentemente dal CARDS [7]. L’HPS, l’ASCOT e il CARDS hanno inoltre trattato migliaia di soggetti ultrasettantenni, rivelando che il “carico aterogeno” in individui anziani, ma senza pregressi eventi, si può ridurre vistosamente tenendo bassi i livelli di lipidi.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliografia
Notarbartolo A (2005) Patogenesi “colesterolica” o “infiammatoria” dell’aterosclerosi: dilemma vero o fittizio? Ann Ital Med Int 20:63–68
[No authors listed] (1984) The Lipid research Clinics Coronary Primary Prevention Trial results. JAMA 251(3):351–364
Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1307
Downs JR, Clerfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis prevention study. JAMA 279:1615–1622
Sever PS, Dalhof B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the anglo-Scandinavian cardiac outcomes trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361:1149–1158
Collins R, Armitage J, Parish S et al (2002) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374):2005–2016
Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364:685–696
Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410–418
Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071–1080
Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes for the Pravastatin or Atorvastatin Evaluation and Infection Therapy. N Engl J Med 350:1495–1504
Nissen SE, Tsunoda T, Tuzcu EM et al (2003) Effects of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 290:2292–2300
Schächinger V, Britten MB, Elsner M et al (1999) A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation 100:1502–1508
Iwasa S, Fan J, Shimokama T et al (1999) Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis 146:93–100
Xu CB, Zhang Y, Stenman E, Edvinsson L (2002) D-Erythro-N,N-dimethylspingosine inhibits bFGF-induced proliferation of cerebral, aortic and coronary smooth muscle cells. Atherosclerosis 164:237–243
Verreth W, De Keyzer D, Pelat M et al (2004) Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptorgamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110:3259–3269
Barani J, Nilsson JA, Mattiasson I et al (2005) Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 42:75–80
Psaty BM, Furberg CD (2005) COX-2 inhibitors-lessons in drug safety. N Engl J Med 352:1133–1135
Pasqui AL, Bova G, Maffei S et al (2005) I mediatori della risposta immunitaria nell’aterosclerosi. Ann Ital Med Int 20:81–89
Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143
Caligiuri G, Paulsson G, Nicoletti A et al (2000) Evidence for antigen-driven T cell response in unstable angina. Circulation 102:1114–1119
Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890
Prasad A, Zhu J, Halcox JP et al (2002) Predisposition to atherosclerosis by infections: role of endothelial disfunction. Circulation 106:184–190
Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanisms regulating Th1 immune responses. Ann Rev Immunol 21:713–758
Lien E, Ingalls RR (2002) Toll-like receptors. Crit Care Med 30:S1–S11
Mayr M, Kiechl S, Willeit J et al (2000) Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori and Cytomegalovirus with immune reactions to Heat-Shock Proteins 60 and carotid or femoral atherosclerosis. Circulation 102:833–839
Xu Q (2002) Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 22:1547–1559
Zal B, Kaski JC, Arno G et al (2004) Heat-shock protein 60-reactive CD4+ CD28 null T cells in patients with acute coronary syndromes. Circulation 109:1230–1235
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
(2010). Teorie degenerativa e infiammatoria e ruolo della risposta immunitaria. In: Aterosclerosi. Springer, Milano. https://doi.org/10.1007/978-88-470-1412-1_7
Download citation
DOI: https://doi.org/10.1007/978-88-470-1412-1_7
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1411-4
Online ISBN: 978-88-470-1412-1
eBook Packages: MedicineMedicine (R0)